Komal Patel
Family · Sterling Heights, MINPI 1518730381
Payments from drug & device makers
Across 47 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$116
- Novo Nordisk$100
- Lilly USA, LLC$89
- AbbVie$77
- Boehringer Ingelheim$62
- Aimmune Therapeutics, Inc.$57
- plus $451 from 16 others
What the payments were for
- Food & beverage$951100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $116 |
| Novo Nordisk | 4 | $100 |
| Lilly USA, LLC | 5 | $89 |
| AbbVie | 4 | $77 |
| Boehringer Ingelheim | 2 | $62 |
| Aimmune Therapeutics, Inc. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $57 |
| AstraZeneca | 3 | $50 |
| GSK | 3 | $48 |
| Exact Sciences | 2 | $43 |
| United Therapeutics Corporation | 1 | $33 |
| Smith+Nephew | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Merck | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Pulmonx Corporation | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
How this compares
$951 in reported general payments places this provider in the 65th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 12 | $13,803 |
| JardianceEmpagliflozin | 19 | $12,976 |
| EliquisApixaban | 13 | $11,717 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,692 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 112 | $1,999 |
| Oxycodone Hcl | 25 | $734 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $611 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 21 | $595 |
| Atorvastatin Calcium | 56 | $538 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $437 |
| Gabapentin | 33 | $413 |
| Losartan Potassium | 51 | $408 |
| Rosuvastatin Calcium | 20 | $385 |
| Alprazolam | 33 | $354 |
| Levothyroxine Sodium | 22 | $332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $100 | $13,80312 claims |
| Boehringer IngelheimJardiance | $62 | $12,97619 claims |
| GSKTrelegy Ellipta | $48 | $7,69212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,657 family providers in Michigan.
Other family in Sterling Heights
- Simona DenkovskiSterling Heights$11K
- Brittany SharpSterling Heights$10K
- Darlene BrownSterling Heights$9K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.